Lung Cancer Diagnostic and Screening Market, By Test Type (Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others) Imaging Test (Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Bi

Lung Cancer Diagnostic and Screening Market, By Test Type (Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others) Imaging Test (Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy), By Cancer Type (Non-small cell lung cancer, Small Cell Lung CancerNeurosurgery), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Lung Cancer Diagnostic and Screening Market, By Test Type (Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others) Imaging Test (Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy), By Cancer Type (Non-small cell lung cancer, Small Cell Lung CancerNeurosurgery), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Lung cancer is a disease caused by uncontrolled cell division in lungs. Cells divide and make more copies of themselves as part of their normal function. The uncontrolled division of damaged cells results in tissue tumors, which eventually prevent organs from functioning properly. Lung cancer start in the lungs, commonly in the airways (bronchi or bronchioles) or small air sacs (alveoli). Cancers that begin in another location and spread to the lungs are typically named after the location of their origin. Lung cancer treatments include surgery, radiofrequency ablation, radiation therapy, chemotherapy, targeted drug therapy, and immunotherapy. Key players in the industry are focusing on the development of technologically advanced products. Thus, the introduction of such advanced products into the market is expected to drive the growth of the global lung cancer diagnostic and screening market over the forecast period.

Market Dynamics

The key players in the industry are focusing on the development of technologically advanced equipment, instruments, and systems for various surgical procedures. Thus, the introduction of such advanced products in the market is expected to drive growth of the global lung cancer diagnostic and screening market over the forecast period. For instance, in May 2021, QIAGEN, a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment.

Key features of the study:

• This report provides an in-depth analysis of the global lung cancer diagnostic and screening market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global lung cancer diagnostic and screening market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Abbott, Amgen Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Lepu Medical Technology(Beijing)Co.,Ltd., AstraZeneca, F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings., Agilent Technologies, Inc., QIAGEN, Quest Diagnostics Incorporated., NeoGenomics Laboratories., Myriad Genetics, Inc., GRAIL, LLC., DELFI Diagnostics.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global lung cancer diagnostic and screening market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lung cancer diagnostic and screening market.

Global Lung Cancer Diagnostic and Screening Market Detailed Segmentation:

• By Test Type:
• Biomarkers Test

EGFR Mutation Test

KRAS Mutation Test

ALK Test

HER2 Test

Others

• Imaging Test

Computed Tomography (CT) scan

Positron Emission Tomography (PET) scan

Chest X-Ray

Others

• Biopsy
• By Cancer Type:
• Non-small cell lung cancer
• Small Cell Lung Cancer
• By End User:
• Hospital Associated Labs
• Independent Diagnostic Laboratories
• Cancer Research Institutes
• Others
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• Company Profiles
• Abbott
• Amgen Inc.,
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Lepu Medical Technology(Beijing)Co.,Ltd.
• AstraZeneca
• Hoffmann-La Roche Ltd
• Laboratory Corporation of America Holdings.
• Agilent Technologies, Inc.
• QIAGEN
• Quest Diagnostics Incorporated.
• NeoGenomics Laboratories.
• Myriad Genetics, Inc.
• GRAIL, LLC.
• DELFI Diagnostics.